SNTI - Senti Biosciences, Inc. Stock Price, Fair Value and News

0.29USD+0.01 (+3.57%)Market Closed

Market Summary

USD0.29+0.01

Market Closed

3.57%

SNTI Stock Price

View Fullscreen

SNTI RSI Chart

SNTI Valuation

Market Cap

13.3M

Price/Earnings (Trailing)

-0.11

Price/Sales (Trailing)

5.18

Price/Free Cashflow

-0.21

SNTI Price/Sales (Trailing)

SNTI Profitability

Return on Equity

-184.42%

Return on Assets

-103.28%

Free Cashflow Yield

-485.59%

SNTI Fundamentals

SNTI Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

SNTI Earnings

Earnings (TTM)

-123.4M

Earnings Growth (Yr)

-22.07%

Earnings Growth (Qtr)

-376.16%

Breaking Down SNTI Revenue

Last 7 days

-6.4%

Last 30 days

-25.6%

Last 90 days

-34.1%

How does SNTI drawdown profile look like?

SNTI Financial Health

Current Ratio

5.62

SNTI Investor Care

Shares Dilution (1Y)

3.81%

Diluted EPS (TTM)

-1.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.5M	4.0M	2.6M	2.6M
2022	3.8M	4.4M	5.0M	4.3M
2021	1.1M	1.7M	2.2M	2.8M
2020	0	0	0	566.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Senti Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	rajangam kanya	acquired	-	-	101,000	chief medical & devt. officer
Feb 01, 2024	lu timothy k	acquired	-	-	306,000	ceo and president
Feb 01, 2024	knobelman deborah	acquired	-	-	101,000	chief financial officer
Oct 03, 2022	knobelman deborah	acquired	-	-	30,000	chief financial officer
Jun 08, 2022	epstein david r	acquired	-	-	112,519	-
Jun 08, 2022	farokhzad omid	acquired	-	-	5,750,000	-
Jun 08, 2022	farokhzad omid	acquired	2,500,000	10.00	250,000	-
Jun 08, 2022	farokhzad omid	sold	-	-	-4,518,100	-
Jun 08, 2022	dynamics sponsor llc	acquired	-	-	5,750,000	-
Jun 08, 2022	dynamics sponsor llc	sold	-	-	-6,465,500	-

Which funds bought or sold SNTI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-8,164	-	-%
Apr 18, 2024	ARK Investment Management LLC	reduced	-17.21	-685,087	615,021	-%
Mar 11, 2024	VANGUARD GROUP INC	added	27.82	238,202	466,654	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	added	50.00	5,770	9,900	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-1,337,000	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	28,844	28,844	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	34,118	95,700	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	18,904	18,904	-%

Are Funds Buying or Selling SNTI?

Are funds buying SNTI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNTI

No. of Funds

Unveiling Senti Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 10, 2023	woodline partners lp	0%	0	SC 13G/A

Recent SEC filings of Senti Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Feb 06, 2024	8-K	Current Report
Feb 02, 2024	4	Insider Trading
Feb 02, 2024	4	Insider Trading
Feb 02, 2024	4	Insider Trading

Peers (Alternatives to Senti Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Senti Biosciences, Inc. News

Latest updates

Senti Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-100.0%	-	338	937	1,286	59.00	1,766	1,358	1,104	793	1,103	793	72.00	-
Operating Expenses	-68.2%	14,040	44,214	20,572	21,120	15,359	16,514	23,129	12,862	11,678	12,526	9,789	9,214	-
S&GA Expenses	-6.5%	8,814	9,431	9,620	9,802	9,453	9,995	13,882	5,259	5,269	7,116	4,554	4,311	-
R&D Expenses	-45.5%	4,955	9,092	10,952	11,318	5,907	6,519	9,247	7,603	6,409	5,410	5,235	4,903	-
Net Income	-376.2%	-71,058	-14,923	-18,697	-18,722	-58,210	-16,640	-11,552	-11,808	-10,904	-11,406	-12,007	-21,002	-
Net Income Margin	-14.2%	-48.18*	-42.20*	-27.74*	-23.53*	-22.91*	-10.14*	-10.48*	-12.16*	-20.04*	-8.98*	-11.94*	-17.82*	-35.09*
Free Cashflow	59.2%	-7,041	-17,237	-17,344	-22,811	-17,539	-24,337	-16,955	-17,439	-15,956	-9,737	-1,354	-8,571	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4
Assets	-9.3%	119	132	144	161	181	189	202	92.00	97.00	232	232	232	171	110	48.00
Current Assets	-9.9%	71.00	79.00	63.00	81.00	103	120	144	45.00	60.00	2.00	2.00	2.00	-	-	32.00
Cash Equivalents	-8.9%	36.00	39.00	37.00	32.00	58.00	115	140	38.00	59.00	74.00	83.00	2.00	26.00	-	31.00
Net PPE	-4.1%	25.00	26.00	59.00	59.00	51.00	47.00	36.00	24.00	12.00	-	-	-	-	-	3.00
Liabilities	7.7%	53.00	49.00	46.00	49.00	54.00	49.00	48.00	42.00	36.00	8.00	8.00	8.00	11.00	14.00	17.00
Current Liabilities	25.3%	13.00	10.00	10.00	13.00	18.00	16.00	18.00	18.00	15.00	0.00	0.00	0.00	-	-	5.00
Shareholder's Equity	-19.3%	67.00	83.00	97.00	112	127	140	154	-	-111	-	5.00	-	0.00	-	-
Retained Earnings	-8.3%	-244	-225	-210	-192	-173	-155	-138	-126	-115	-6.52	-6.23	-6.00	0.00	0.00	-59.76
Additional Paid-In Capital	0.9%	311	309	308	304	301	295	293	5.00	4.00	-	-	-	0.00	0.00	1.00
Accumulated Depreciation	17.8%	6.00	5.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	-	-	-	-	-	1.00
Shares Outstanding	2.7%	46.00	44.00	44.00	44.00	44.00	43.00	13.00	3.00	3.00	3.00	3.00	-	15.00	5.00	14.00
Float	-	30.00	-	24.00	-	-	-	75.00	-	-	-	229	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2020Q4
Cashflow From Operations	54.2%	-7,037	-15,379	-13,675	-16,304	-9,006	-10,136	-5,695	-10,059	-11,971	-8,805	-934	-8,365	-	-
Share Based Compensation	404.6%	2,064	409	3,434	3,763	4,216	2,290	9,225	661	735	626	562	372	-	-
Cashflow From Investing	-99.5%	101	21,142	18,331	-9,497	-49,118	-14,201	-11,260	-7,380	-	-	-230,000	-206	-	-
Cashflow From Financing	2517.4%	556	-23.00	281	-35.00	876	-485	118,615	-455	-	-	232,032	3,558	-	-

SNTI Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Contract revenue	$ 1,978	$ 3,286
Grant income	583	1,000
Total revenue	2,561	4,286
Operating expenses
Research and development (included related party cost of $3,113 and $—, respectively)	32,150	28,145
General and administrative	37,176	38,225
Loss on impairment of fixed assets	25,962	0
Total operating expenses	95,288	66,370
Loss from operations	(92,727)	(62,084)
Other income (expense)
Interest income, net	2,864	1,701
Change in fair value of contingent earnout liability	207	9,461
Gain on extinguishment of convertible notes	0	1,289
GeneFab sublease income - related party	2,323	0
Other income (expense)	(33)	(32)
Total other income (expense), net	9,321	12,419
Net loss from continuing operations	(83,406)	(49,665)
Net income (loss) from discontinued operations	12,348	(8,545)
Net loss	(71,058)	(58,210)
Other comprehensive gain (loss)
Unrealized gain (loss) on investments	(1)	1
Comprehensive loss	$ (71,059)	$ (58,209)
Net loss per share from continuing operations, basic (in dollars per share)	$ (1.88)	$ (1.90)
Net loss per share from continuing operations, diluted (in dollars per share)	(1.88)	(1.90)
Net income (loss) per share from discontinued operations, basic (in dollars per share)	0.28	(0.33)
Net income (loss) per share from discontinued operations, diluted (in dollars per share)	0.28	(0.33)
Net loss per share, basic (in dollars per share)	(1.60)	(2.23)
Net loss per share, diluted (in dollars per share)	$ (1.60)	$ (2.23)
Weighted-average shares outstanding, basic (in shares)	44,372,223	26,110,785
Weighted-average shares outstanding, diluted (in shares)	44,372,223	26,110,785
GeneFab Option
Other income (expense)
Change in fair value	$ 3,318	$ 0
GeneFab Note Receivable
Other income (expense)
Change in fair value	626	0
GeneFab Economic Share
Other income (expense)
Change in fair value	$ 16	$ 0

SNTI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 35,926	$ 57,621
Short-term investments	0	40,942
Current assets of discontinued operations	0	209
Total current assets	71,200	102,579
Restricted cash	3,522	3,366
GeneFab receivable - related party, net of current portion	1,119	0
Property and equipment, net	25,338	51,361
Operating lease right-of-use assets	16,274	18,418
GeneFab Economic Share - related party	1,816	0
Other long-term assets	215	283
Noncurrent assets of discontinued operations	0	4,785
Total assets	119,484	180,792
Liabilities and Stockholders’ Equity
Accounts payable	1,250	1,370
Finance lease liabilities, current portion	97	0
Early exercise liability, current portion	135	135
Deferred revenue	0	799
GeneFab sublease deferred income - related party	989	0
Accrued expenses and other current liabilities	5,927	12,576
Operating lease liabilities	4,031	1,988
Current liabilities of discontinued operations	243	1,185
Total current liabilities	12,672	18,053
Operating lease liabilities, net of current portion	33,538	35,103
Contingent earnout liability	20	227
GeneFab Option - related party	6,331	0
Early exercise liability, net of current portion	10	146
Total liabilities	52,571	53,529
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2023 and December 31, 2022; 45,700,161 and 44,062,534 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	5	4
Additional paid-in capital	311,252	300,544
Accumulated other comprehensive income	0	1
Accumulated deficit	(244,344)	(173,286)
Total stockholders’ equity	66,913	127,263
Total liabilities, redeemable convertible preferred stock and stockholders’ equity	119,484	180,792
Nonrelated Party
Assets
Accounts receivable	112	626
Prepaid expenses and other current assets	2,783	3,181
Related Party
Assets
Accounts receivable	17,592	0
Prepaid expenses and other current assets	$ 14,787	$ 0

About Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

CEO	Dr. Timothy K. Lu M.D., Ph.D.
WEBSITE	sentibio.com
INDUSTRY	Biotechnology
EMPLOYEES	122

Senti Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Senti Biosciences, Inc.? What does SNTI stand for in stocks?

SNTI is the stock ticker symbol of Senti Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Senti Biosciences, Inc. (SNTI)?

As of Fri Apr 26 2024, market cap of Senti Biosciences, Inc. is 13.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers. The fair value of Senti Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Senti Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Senti Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNTI is over valued or under valued. Whether Senti Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Senti Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNTI.

What is Senti Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, SNTI's PE ratio (Price to Earnings) is -0.11 and Price to Sales (PS) ratio is 5.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNTI PE ratio will change depending on the future growth rate expectations of investors.